|Assessment Status||NCPE Assessment Process Complete|
|Indication||For the first-line treatment of adult patients with ALK+ advanced NSCLC|
|Rapid review commissioned||08/11/2017|
|Rapid review completed||04/12/2017|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full pharmacoeconomic assessment commissioned by HSE||20/12/2017|
|Pre-submission consultation with Applicant||13/02/2018|
|Full submission received from Applicant||25/04/2018|
|Preliminary review sent to Applicant||15/10/2018|
|NCPE assessment re-commenced||30/10/2018|
|Factual accuracy sent to Applicant||05/12/2018|
|NCPE assessment re-commenced||19/12/2018|
|NCPE assessment completed||15/01/2019|
|NCPE assessment outcome||Following assessment of the applicant’s submission the NCPE recommends that alectinib (Alecensa®), for the first line treatment of adult patients with ALK-positive advanced NSCLC, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.|
This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations June 2019.